肾源性系统性纤维化疾病的化学机制和双鳌合剂法的抑制研究

doi:10.3866/PKU.DXHX202209029

大学化学 >> 2023, Vol. 38 >> Issue (12): 86-90.doi: 10.3866/PKU.DXHX202209029

所属专题：大学化学基础与创新药物研发前沿

肾源性系统性纤维化疾病的化学机制和双鳌合剂法的抑制研究

詹心琪¹^,*(), 周朝晖²^,³^,*()

¹ 厦门大学医学院, 福建厦门 361005
² 固体表面物理化学国家重点实验室, 福建厦门 361005
³ 厦门大学化学化工学院, 福建厦门 361005

收稿日期:2022-09-12 录用日期:2022-11-23 发布日期:2023-01-06
通讯作者: 詹心琪,周朝晖 E-mail:zxq@xmu.edu.cn;zhzhou@xmu.edu.cn
基金资助:
国家自然科学基金(22179110)

Chemical Mechanism of Nephrogenic Systemic Fibrosis and Its Inhibition with Double Chelation

Xinqi Zhan¹^,*(), Zhaohui Zhou²^,³^,*()

¹ Medical College, Xiamen University, Xiamen 361005, Fujian Province, China
² State Key Laboratory of Physical Chemistry of Solid Surfaces, Xiamen 361005, Fujian Province, China
³ College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, Fujian Province, China

Received:2022-09-12 Accepted:2022-11-23 Published:2023-01-06
Contact: Xinqi Zhan, Zhaohui Zhou E-mail:zxq@xmu.edu.cn;zhzhou@xmu.edu.cn

摘要/Abstract

摘要：

少数肾病患者使用核磁共振钆造影剂导致肾源性系统性纤维化(NSF)。本文在介绍钆造影剂的基础上，阐述了NSF在生物体内的转化与沉积的机理，揭示了肾源性系统纤维化沉积物的磷酸钆生物微粒形成的化学本质。这有助于进一步了解肾源性系统纤维化的发生、发展和形成机制。并提出在钆造影剂体系中引入具有生物兼容性的第二螯合剂的新思路，以提高造影剂使用的安全性。

关键词: 肾源性系统性纤维化, 钆造影剂, 螯合剂, 化学机制

Abstract:

A small proportion of nephropathy patients administered gadolinium contrast agents for nuclear magnetic resonance have been reported to develop nephrogenic systemic fibrosis (NSF). This paper introduces the mechanism of the transformation and deposition of NSF, aiming to reveal the chemical nature of the gadolinium phosphate bioparticles in nephrogenic system fibrosis. This research will provide an important theoretical basis for future studies on the occurrence, development, and formation of nephrogenic system fibrosis and the removal of sediment residues. Moreover, a new idea for introducing a biocompatible second chelating agent into the gadolinium contrast agent system has been proposed, which aims to improve the safe use of gadolinium contrast agent.

Key words: Nephrogenic systemic fibrosis, Gadolinium contrast agent, Chelation, Chemical mechanism

詹心琪, 周朝晖. 肾源性系统性纤维化疾病的化学机制和双鳌合剂法的抑制研究[J]. 大学化学, 2023, 38(12): 86-90.

Xinqi Zhan, Zhaohui Zhou. Chemical Mechanism of Nephrogenic Systemic Fibrosis and Its Inhibition with Double Chelation[J]. University Chemistry, 2023, 38(12): 86-90.

链接本文: https://www.dxhx.pku.edu.cn/CN/10.3866/PKU.DXHX202209029

https://www.dxhx.pku.edu.cn/CN/Y2023/V38/I12/86

图/表 4

图1

图2

图3

图4

参考文献 29

1	漆剑频; 王承缘. 放射诊断临床指南, 第2版北京: 科学出版社, 2005, 32- 57.
2	段二月; 马建功; 程鹏. 大学化学, 2016, 31 (7), 1.
3	蒋尚达. 大学化学, 2019, 34 (12), 73.
4	Carr D. H. ; Brown J. ; Bydder G. M. ; Steiner R. E. ; Weinmann H. J. ; Speck U. ; Hall A. S. I. ; Young R. Am. J. Roentgenol. 1984, 143 (2), 215. doi: 10.2214/ajr.143.2.215
5	Weinmann H. J. ; Brasch R. C. ; Press W. R. Am. J. Roentgenol. 1984, 142 (3), 619. doi: 10.2214/ajr.142.3.619
6	刘洪涛; 陈曦; 沈素云; 蒋超; 冯顺卿. 分析测试学报, 2021, 40 (6), 876. doi: 10.3969/j.issn.1004-4957.2021.06.013
7	Bulte J. W. M. ; Kraitchman D. L. NMR Biomed. 2004, 17 (7), 484. doi: 10.1002/nbm.924
8	Caravan P. ; Ellison J. J. ; McMurry T. J. ; Lauffer R. B. Chem. Rev. 1999, 99 (9), 2293. doi: 10.1021/cr980440x
9	Caravan P. Chem. Soc. Rev. 2006, 35 (6), 512. doi: 10.1039/b510982p
10	Cowper S. E. ; Robin H. S. ; Steinberg S. M. ; Su L. D. ; Gupta S. ; LeBoit P. E. Lancet 2000, 356 (9234), 1000. doi: 10.1016/S0140-6736(00)02694-5
11	Cowper S. E. ; Su L. D. ; Bhawan J. ; Robin H. S. ; LeBoit P. E. Am. J. Dermatopathol. 2001, 23 (5), 383. doi: 10.1097/00000372-200110000-00001
12	Grobner T. Nephrol. Dial. Transplant 2006, 21 (4), 1104. doi: 10.1093/ndt/gfk062
13	Marckmann P. ; Skov L. ; Rossen K. ; Dupont A. ; Damholt M. B. ; Heaf J. ; Thomsen H. S.J. Am. Soc. Nephrol. 2006, 17 (9), 2359. doi: 10.1681/ASN.2006060601
14	Thomsen H. S. ; Morcos S. K. ; Dawson P. Clin. Radiol. 2006, 61 (11), 905. doi: 10.1016/j.crad.2006.09.003
15	Murphy K. J. ; Brunberg J. A. ; Cohan R. H. Am. J. Roentgenol. 1996, 167 (4), 847. doi: 10.2214/ajr.167.4.8819369
16	FDA drug safety communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction.[2023-01-06]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warnings-using-gadolinium-based-contrast-agents-patients-kidney
17	CDC: Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents.[2023-01-06]. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5607a1.htm
18	MRI questions and answers. International Society for Magnetic Resonance in Medicine.[2023-01-06]. https://www.ismrm.org/
19	Wahsner J. ; Gale E. M. ; Rodriguez R. A. ; Caravan P. Chem. Rev. 2019, 119 (2), 957. doi: 10.1021/acs.chemrev.8b00363
20	Boyd A. S. ; Zic J. A. ; Abraham J. L.J. Am. Acad. Dermatol. 2007, 56 (1), 27. doi: 10.1016/j.jaad.2006.10.048
21	Boyd A. S. ; Sanyal S. ; Abraham J. L.J. Am. Acad. Dermatol. 2010, 62 (2), 337. doi: 10.1016/j.jaad.2009.04.010
22	Abraham J. L. ; Thakral C. ; Skov L. ; Rossen K. ; Marckmann P. Brit. J. Dermatol. 2008, 158 (2), 273.
23	George S. J. ; Webb S. M. ; Abraham J. L. ; Cramer S. P. Brit. J. Dermatol. 2010, 163 (5), 1077. doi: 10.1111/j.1365-2133.2010.09918.x
24	Lessing P. A. ; Erickson A. W.J. Euro. Ceram. Soc. 2003, 23 (16), 3049. doi: 10.1016/S0955-2219(03)00100-6
25	Gao S. ; George S. ; Zhou Z. H. Dalton Trans. 2016, 45 (12), 5388. doi: 10.1039/C5DT04172D
26	Chen M. L. ; Tang X. ; Lu T. H. ; Zhan X. Q. ; Zhou Z. H.J. Coord. Chem. 2020, 72 (9), 1547.
27	Gao S. ; Chen M. L. ; Zhou Z. H. Dalton Trans. 2014, 43 (2), 639.
28	Scott L. J.Clin. Drug Invest. 2018, 38 (9), 773.
29	Ponrartana S. ; Moore M. M. ; Chan S. S. ; Victoria T. ; Dillman J. R. ; Chavhan G. B. Pediatr. Radiol. 2021, 51 (5), 736.

肾源性系统性纤维化疾病的化学机制和双鳌合剂法的抑制研究

Chemical Mechanism of Nephrogenic Systemic Fibrosis and Its Inhibition with Double Chelation

RichHTML

PDF

赞

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 29

相关文章 1

Metrics

推荐阅读 0